Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

The Effects of Whole-Body Vibration Training on Clinical and Functional Outcomes in Individuals Diagnosed With Interstitial Lung Disease

16 juli 2026 uppdaterad av: Fahrettin Özelçi, Istinye University

The Effects of Whole-Body Vibration Training on Clinical and Functional Outcomes in Individuals Diagnosed With Interstitial Lung Disease: A Randomized Controlled Trial

This randomized controlled trial aims to investigate the clinical and functional effects of Whole Body Vibration (WBV) training when added to a standard pulmonary rehabilitation (PR) program in patients with fibrotic interstitial lung disease (ILD). Participants aged between 40 and 80 years with confirmed ILD diagnosis will be randomly assigned to two groups: (1) PR only (control), and (2) PR + WBV (intervention). The program will last for 8 weeks, with supervised sessions twice per week.

Primary outcome measures include pulmonary function (FEV₁, FVC), exercise capacity (6-minute walk test), dyspnea (mMRC and Borg scale), arterial blood gas analysis, depression level (Beck Depression Inventory), and disease-specific quality of life (St. George's Respiratory Questionnaire). WBV will be performed using a side-alternating vibration platform starting at 10 Hz and progressively increased up to 24-26 Hz over 8 weeks. All procedures will follow ATS/ERS guidelines.

This study is conducted at the Chest Diseases Department of Sultan Abdulhamid Han Training and Research Hospital in Istanbul under the supervision of a multidisciplinary team. The goal is to determine whether WBV offers additional benefit in improving functional outcomes, respiratory performance, and quality of life in ILD patients undergoing PR.

Studieöversikt

Detaljerad beskrivning

  1. Study Background and Aim Interstitial lung disease (ILD) is characterized by inflammation and progressive fibrosis, leading to restrictive respiratory patterns, exertional dyspnea, and reduced exercise capacity. While pulmonary rehabilitation (PR) is a cornerstone of clinical management, data regarding the efficacy of Whole-Body Vibration Training (WBVT) in this population remain limited. The aim of this study is to investigate the effectiveness of WBVT applied in addition to a routine PR program consisting of respiratory muscle training, peripheral muscle training, and aerobic exercise in individuals with ILD. This randomized controlled trial comprehensively evaluates the clinical and functional effects of WBVT, focusing on lung functions, functional exercise capacity, gas exchange capacity via arterial blood gas analysis, multidimensional dyspnea levels, psychological status, and quality of life.
  2. Study Design and Population This is a two-arm, prospective, randomized controlled trial conducted at the Pulmonary Rehabilitation Unit of the Pulmonology Department at Istanbul Sultan Abdülhamid Han Training and Research Hospital. Patients aged 40-80 years diagnosed with ILD will be screened. Following cardiovascular suitability clearance by a cardiologist, participants will be randomly assigned to either the Control Group (PR alone) or the Study Group (PR + WBVT) using a computer-based block randomization method. All procedures align with the Declaration of Helsinki, and written informed consent will be obtained.
  3. INTERVENTIONS 3.1. Control Group (CG) - Standard Pulmonary Rehabilitation Participants in the control group will receive a supervised standard pulmonary rehabilitation (PR) program twice a week for 8 weeks. This program includes active cycle of breathing, diaphragmatic, and pursed-lip breathing techniques, alongside three structured training modalities. First, Inspiratory Muscle Training will be performed using the Powerbreathe Medic Plus (gray) device twice weekly, with the initial load set at a rating of perceived exertion (RPE) of 3-4 on the Modified Borg Scale and increased by 5-10% weekly (5 breaths × 6 sets). Second, Peripheral Muscle Training will target the quadriceps, shoulder flexors, and shoulder abductors at an RPE of 3-4, structured as 2 sets of 8 repetitions. Third, the Aerobic Exercise Program will be conducted on a cycle ergometer twice weekly for 21 minutes (3-minute warm-up, 15-minute target-intensity, and 3-minute cool-down) at 60-80% of the target heart rate calculated via the Karvonen formula, with pedal resistance adjusted weekly by 5-10% to maintain an RPE of 3-4.

    3.2. Study Group (SG) - Pulmonary Rehabilitation + Whole-Body Vibration Training (WBVT)Participants in the study group will receive the identical 8-week standard PR program described for the control group, combined with a supervised WBVT protocol performed twice a week using the Power Plate ProXG10 Acceleration Pro series platform. During WBVT, participants stand barefoot on the platform with slight knee flexion (~150°). Each session begins with a 5-minute warm-up (low-intensity treadmill walking/cycling and stretching) and concludes with a 5-minute cool-down consisting of static stretching. For the first 4 weeks, WBVT will be applied as 2 sets of 3 minutes with 2-minute rest intervals, starting at a frequency of 10 Hz and increasing by 2-3 Hz weekly based on tolerance. From week 5 through week 8, the training volume will increase to 3 sets of 3 minutes, progressively raising the frequency to reach a target of 24-26 Hz. The vibration amplitude will be kept constant at approximately 4-6 mm throughout the entire 8-week intervention.

  4. STATISTICAL METHODOLOGY Sample Size and Statistical Analysis Based on a two-tailed independent samples t-test for the primary outcome, assuming a significance level of $\alpha = 0.05$, a statistical power ($1-\beta$) of 0.80, and an expected effect size of Cohen's $d = 1.15$ calculated via G*Power 3.1, a minimum sample size of 26 participants (13 per group) is required. To account for a potential 15% attrition rate, additional participants will be recruited. Statistical analysis will be performed using IBM SPSS Statistics V26.0 software. Normality will be assessed with the Shapiro-Wilk test. Continuous variables will be analyzed using Mixed Design ANOVA or appropriate parametric/non-parametric tests (Student's t-test, Paired t-test, Mann-Whitney U, Wilcoxon signed-rank) depending on the distribution of the data, with statistical significance set at $p < 0.05$.

Studietyp

Interventionell

Inskrivning (Faktisk)

26

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Istanbul
      • Üsküdar, Istanbul, Turkiet (Türkiye)
        • Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria

  • Ages 40 to 80 years
  • Diagnosis of fibrotic interstitial lung disease confirmed by a multidisciplinary council (e.g., idiopathic pulmonary fibrosis, idiopathic nonspecific interstitial pneumonia, sarcoidosis, or other fibrotic patterns)
  • Receiving stable pharmacological treatment for at least 3 months (e.g., antifibrotic or immunosuppressive therapy)
  • No acute exacerbation or upper respiratory tract infection within the past 4 weeks
  • Able to safely participate in pulmonary rehabilitation and whole-body vibration training as determined by clinical evaluation

Exclusion Criteria:

  • Pulmonary hypertension with systolic pulmonary artery pressure >65 mmHg
  • Severe cardiovascular disease (e.g., uncontrolled hypertension, congestive heart failure, recent myocardial infarction)
  • Advanced renal or hepatic failure
  • Balance disorders preventing safe standing on a vibration platform
  • Severe musculoskeletal limitations (e.g., advanced arthritis, severe osteoporosis, high fall risk)
  • Advanced cognitive impairment or dementia
  • Severe psychiatric disorders (e.g., severe depression or anxiety)
  • Neurological diseases interfering with participation or test performance
  • Participation in a pulmonary rehabilitation program during the study or within the past 6 months
  • Pregnancy or breastfeeding
  • Uncontrolled metabolic diseases (e.g., advanced diabetes, uncontrolled thyroid dysfunction)
  • Vestibular system disorders
  • Active malignancy
  • Presence of a pacemaker or other contraindicated implanted electronic devices

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Pulmonary Rehabilitation Only

Participants in this group will receive a supervised pulmonary rehabilitation (PR) program consisting of inspiratory muscle training, peripheral muscle strengthening exercises, aerobic exercise training, and breathing techniques (diaphragmatic breathing, pursed-lip breathing, and active cycle of breathing techniques). The PR program will be administered twice weekly for 8 weeks under clinical supervision.

Intervention Names included in this Arm (must match Intervention list):

Inspiratory Muscle Training

Peripheral Muscle Strengthening Exercises

Aerobic Exercise Training (Cycle Ergometer)

Breathing Techniques

Inspiratory muscle training performed using the PowerBreathe Medic Plus device twice weekly for 8 weeks. Training follows a 5 breaths × 6 sets protocol, with the initial load set to achieve an RPE of 3-4 on the Modified Borg Scale. Load is increased weekly by 5-10% according to patient tolerance.
Resistance exercises targeting the quadriceps, shoulder flexors, and shoulder abductors performed at an RPE of 3-4, for 2 sets of 8 repetitions. Sessions occur twice weekly for 8 weeks under supervision.
Aerobic exercise performed on a cycle ergometer at 60-80% of the target heart rate calculated using the Karvonen formula. Each session includes 3 minutes warm-up, 15 minutes active exercise, and 3 minutes cool-down (total 21 minutes). Resistance is adjusted weekly by 5-10% to maintain an RPE of 3-4. Conducted twice weekly for 8 weeks.
Experimentell: Pulmonary Rehabilitation + Whole-Body Vibration Training (WBVT)
Participants in this arm will receive a supervised pulmonary rehabilitation program consisting of inspiratory muscle training, peripheral muscle strengthening exercises, aerobic exercise training, and breathing techniques, administered twice weekly for 8 weeks. In addition, they will receive whole-body vibration training using a side-alternating vibration platform (Power Plate ProXG10). Vibration training will start at 10 Hz and progressively increase to 24-26 Hz over 8 weeks, performed as 2-3 sets of 3 minutes each, targeting an RPE of 3-4.
Inspiratory muscle training performed using the PowerBreathe Medic Plus device twice weekly for 8 weeks. Training follows a 5 breaths × 6 sets protocol, with the initial load set to achieve an RPE of 3-4 on the Modified Borg Scale. Load is increased weekly by 5-10% according to patient tolerance.
Resistance exercises targeting the quadriceps, shoulder flexors, and shoulder abductors performed at an RPE of 3-4, for 2 sets of 8 repetitions. Sessions occur twice weekly for 8 weeks under supervision.
Aerobic exercise performed on a cycle ergometer at 60-80% of the target heart rate calculated using the Karvonen formula. Each session includes 3 minutes warm-up, 15 minutes active exercise, and 3 minutes cool-down (total 21 minutes). Resistance is adjusted weekly by 5-10% to maintain an RPE of 3-4. Conducted twice weekly for 8 weeks.
Whole-body vibration training performed using the Power Plate ProXG10 Acceleration Pro series device, twice weekly for 8 weeks. Sessions include warm-up, vibration training, and cool-down components. Vibration begins at 10 Hz and increases gradually by 2-3 Hz each week, reaching 24-26 Hz by week 8. Amplitude is maintained at 4-6 mm. WBVT is applied as 2 sets × 3 minutes initially, with 2 minutes rest between sets, progressing to 3 sets × 3 minutes from week 5 onward. Participants stand barefoot with slight knee flexion (approximately 150°) while maintaining an RPE of 3-4.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Six-Minute Walk Distance
Tidsram: Baseline and after 8 weeks
Functional exercise capacity assessed with the six-minute walk test according to ATS guidelines. Distance in meters will be recorded.
Baseline and after 8 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Forced Vital Capacity (FVC, % predicted)
Tidsram: Baseline and 8 weeks
Pulmonary function will be evaluated by spirometry according to ATS/ERS standards. FVC (% predicted) will be recorded.
Baseline and 8 weeks
Forced Expiratory Volume in 1 Second (FEV1, % predicted)
Tidsram: Baseline and 8 weeks
Spirometry measurement of FEV1 (% predicted).
Baseline and 8 weeks
FEV1/FVC Ratio (%)
Tidsram: Baseline and 8 weeks
Ratio of forced expiratory volume in one second to forced vital capacity.
Baseline and 8 weeks
Partial Pressure of Oxygen (PaO2, mmHg)
Tidsram: Baseline and 8 weeks
Resting arterial blood gas analysis, measuring oxygen tension (PaO2).
Baseline and 8 weeks
Partial Pressure of Carbon Dioxide (PaCO2, mmHg)
Tidsram: Baseline and 8 weeks
Resting arterial blood gas analysis measuring PaCO2.
Baseline and 8 weeks
Blood pH
Tidsram: Baseline and 8 weeks
Arterial blood gas analysis measuring systemic pH.
Baseline and 8 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 januari 2026

Primärt slutförande (Faktisk)

1 juli 2026

Avslutad studie (Faktisk)

1 juli 2026

Studieregistreringsdatum

Först inskickad

24 augusti 2025

Först inskickad som uppfyllde QC-kriterierna

14 juli 2026

Första postat (Faktisk)

16 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera